FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula [I-c] or a pharmaceutically acceptable salt thereof, having mPGES-1 inhibitory activity.
EFFECT: obtaining new compounds that have an inhibitory activity of mPGES-1 and can be used to obtain an inhibitor of mPGES-1.
12 cl, 6 tbl, 145 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRIAZINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | 2015 |
|
RU2692789C2 |
| COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2022 |
|
RU2840068C2 |
| 5-HETEROCYCLO-1,5-BENZODIAZEPINES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | 1995 |
|
RU2152939C1 |
| TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNELS INHIBITOR | 2013 |
|
RU2645158C2 |
| HALOGEN SUBSTITUTED HETEROCYCLIC COMPOUND SALT | 2015 |
|
RU2689315C2 |
| CONDENSED HETEROCYCLIC NITROGEN COMPOUNDS AND USING THEM AS INHIBITORS OF AMYLOID BETA PRODUCTION | 2010 |
|
RU2515976C2 |
| 1-HETEROCYCLYLSULPHONYL, 2-AMINOMETHYL, 5-(HETERO)ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | 2006 |
|
RU2415838C2 |
| HETEROCYCLIC COMPOUND | 2017 |
|
RU2748693C2 |
| TRIAZINE DERIVATIVES FOR TREATING DISEASES ASSOCIATED WITH NEUROTROPHINS | 2019 |
|
RU2816837C2 |
| DERIVATIVES OF PYRIDAZINONE AND TRIAZINONE AND THEIR USING AS PHARMACEUTICAL PREPARATIONS | 2001 |
|
RU2279428C2 |
